Leveraged Long + Income HIMS ETF
HIMY
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Scott Snyder
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 234 West Florida Street Milwaukee NY United States of America 53204
- IPO Date
- Aug 19, 2025
- Similar Companies
- Business
- Defiance Leveraged Long + Income HIMS ETF (HIMY) is an actively managed exchange-traded fund that seeks long-term capital appreciation through approximately 150% to 200% leveraged exposure to the daily share price performance of Hims & Hers Health, Inc. (HIMS), with a secondary objective of generating current income via an options-based credit call spread strategy; the fund employs swap agreements, short-dated in-the-money call options, and U.S. Treasury bills as collateral, while top holdings include multiple HIMS total return swaps with counterparties such as Cantor and Marex, HIMS call options across various strikes, and cash equivalents. HIMY distributes income on a weekly basis, with recent payouts ranging from $0.2607 to $0.5127 per share through late 2025, achieving a distribution rate of 125.0% as of November 13, 2025, and a 30-day SEC yield of -1.02% as of October 31, 2025. Launched on August 18, 2025, by Defiance ETFs—a firm founded in 2018 and focused on thematic, income, and leveraged single-stock products—HIMY operates as a series of Tidal Trust II, with principal executive offices in Milwaukee, Wisconsin, and trades on Nasdaq with an expense ratio of 1.51% and assets under management recently approximating $5 million. In a recent strategic expansion, Defiance ETFs introduced HIMY alongside two companion leveraged income ETFs—PLT for Palantir Technologies and HOOI for Robinhood Markets—on August 18, 2025, marking the firm's push into amplified single-stock exposure paired with yield-enhancing overlays amid growing demand for high-growth telehealth and fintech plays. The fund targets sophisticated investors seeking volatility-driven returns from HIMS's direct-to-consumer wellness platform, with no reported acquisitions, funding rounds, or operational reorganizations since inception, though performance has reflected HIMS stock fluctuations, including a 52-week range from $7.51 to $28.09.